| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
INVITED REVIEWS
Department of Medicine, Division of Endocrinology, Diabetes and Medical Genetics, Medical University of South Carolina, Charleston, South Carolina
The hexosamine biosynthesis pathway (HBP) is a relatively minor branch of glycolysis. Fructose 6-phosphate is converted to glucosamine 6-phosphate, catalyzed by the first and rate-limiting enzyme glutamine:fructose-6-phosphate amidotransferase (GFAT). The major end product is UDP-N-acetylglucosamine (UDP-GlcNAc). Along with other amino sugars generated by HBP, it provides essential building blocks for glycosyl side chains, of proteins and lipids. UDP-GlcNAc regulates flux through HBP by regulating GFAT activity and is the obligatory substrate of O-GlcNAc transferase. The latter is a cytosolic and nuclear enzyme that catalyzes a reversible, posttranslational protein modification, transferring GlcNAc in O-linkage (O-GlcNAc) to specific serine/threonine residues of proteins. The metabolic effects of increased flux through HBP are thought to be mediated by increasing O-GlcNAcylation. Several investigators proposed that HBP functions as a cellular nutrient sensor and plays a role in the development of insulin resistance and the vascular complications of diabetes. Increased flux through HBP is required and sufficient for some of the metabolic effects of sustained, increased glucose flux, which promotes the complications of diabetes, e.g., diminished expression of sarcoplasmic reticulum Ca2+-ATPase in cardiomyocytes and induction of TGF-
and plasminogen activator inhibitor-1 in vascular smooth muscle cells, mesangial cells, and aortic endothelial cells. The mechanism was consistent with enhanced O-GlcNAcylation of certain transcription factors. The role of HBP in the development of insulin resistance has been controversial. There are numerous papers showing a correlation between increased flux through HBP and insulin resistance; however, the causal relationship has not been established. More recent experiments in mice overexpressing GFAT in muscle and adipose tissue or exclusively in fat cells suggest that the latter develop in vivo insulin resistance via cross talk between fat cells and muscle. Although the relationship between HBP and insulin resistance may be quite complex, it clearly deserves further study in concert with its role in the complications of diabetes.
hexosamine biosynthesis pathway; N-acetylglucosamine; O-linked N-acetylglucosamine; modification of proteins
This article has been cited by other articles:
|
|
 |
|
  A. L. Klein, M. N. Berkaw, M. G. Buse, and L. E. Ball O-Linked N-Acetylglucosamine Modification of Insulin Receptor Substrate-1 Occurs in Close Proximity to Multiple SH2 Domain Binding Motifs Mol. Cell. Proteomics, December 1, 2009; 8(12): 2733 - 2745. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. G. Rajapakse, X.-F. Ming, J. M. Carvas, and Z. Yang The hexosamine biosynthesis inhibitor azaserine prevents endothelial inflammation and dysfunction under hyperglycemic condition through antioxidant effects Am J Physiol Heart Circ Physiol, March 1, 2009; 296(3): H815 - H822. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Eguchi, N. Oshiro, T. Miyamoto, K.-i. Yoshino, S. Okamoto, T. Ono, U. Kikkawa, and K. Yonezawa AMP-activated protein kinase phosphorylates glutamine : fructose-6-phosphate amidotransferase 1 at Ser243 to modulate its enzymatic activity. Genes Cells, February 1, 2009; 14(2): 179 - 189. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Jobgen, C. J. Meininger, S. C. Jobgen, P. Li, M.-J. Lee, S. B. Smith, T. E. Spencer, S. K. Fried, and G. Wu Dietary L-Arginine Supplementation Reduces White Fat Gain and Enhances Skeletal Muscle and Brown Fat Masses in Diet-Induced Obese Rats J. Nutr., February 1, 2009; 139(2): 230 - 237. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Laczy, B. G. Hill, K. Wang, A. J. Paterson, C. R. White, D. Xing, Y.-F. Chen, V. Darley-Usmar, S. Oparil, and J. C. Chatham Protein O-GlcNAcylation: a new signaling paradigm for the cardiovascular system Am J Physiol Heart Circ Physiol, January 1, 2009; 296(1): H13 - H28. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. A. Soesanto, B. Luo, D. Jones, R. Taylor, J. S. Gabrielsen, G. Parker, and D. A. McClain Regulation of Akt signaling by O-GlcNAc in euglycemia Am J Physiol Endocrinol Metab, October 1, 2008; 295(4): E974 - E980. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Copeland, J. W. Bullen, and G. W. Hart Cross-talk between GlcNAcylation and phosphorylation: roles in insulin resistance and glucose toxicity Am J Physiol Endocrinol Metab, July 1, 2008; 295(1): E17 - E28. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Champattanachai, R. B. Marchase, and J. C. Chatham Glucosamine protects neonatal cardiomyocytes from ischemia-reperfusion injury via increased protein O-GlcNAc and increased mitochondrial Bcl-2 Am J Physiol Cell Physiol, June 1, 2008; 294(6): C1509 - C1520. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Dentin, S. Hedrick, J. Xie, J. Yates III, and M. Montminy Hepatic Glucose Sensing via the CREB Coactivator CRTC2 Science, March 7, 2008; 319(5868): 1402 - 1405. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E.-G. Hong, D. Y. Jung, H. J. Ko, Z. Zhang, Z. Ma, J. Y. Jun, J. H. Kim, A. D. Sumner, T. C. Vary, T. W. Gardner, et al. Nonobese, insulin-deficient Ins2Akita mice develop type 2 diabetes phenotypes including insulin resistance and cardiac remodeling Am J Physiol Endocrinol Metab, December 1, 2007; 293(6): E1687 - E1696. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. H. McNulty Hexosamine biosynthetic pathway flux and cardiomyopathy in type 2 diabetes mellitus. Focus on "Impact of type 2 diabetes and aging on cardiomyocyte function and O-linked N-acetylglucosamine levels in the heart" Am J Physiol Cell Physiol, April 1, 2007; 292(4): C1243 - C1244. [Full Text] [PDF]
|
|
|
|
|
|
K. A. Robinson, L. E. Ball, and M. G. Buse Reduction of O-GlcNAc protein modification does not prevent insulin resistance in 3T3-L1 adipocytes Am J Physiol Endocrinol Metab, March 1, 2007; 292(3): E884 - E890. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Fulop, R. B. Marchase, and J. C. Chatham Role of protein O-linked N-acetyl-glucosamine in mediating cell function and survival in the cardiovascular system Cardiovasc Res, January 15, 2007; 73(2): 288 - 297. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Muniyappa, R. J. Karne, G. Hall, S. K. Crandon, J. A. Bronstein, M. R. Ver, G. L. Hortin, and M. J. Quon Oral Glucosamine for 6 Weeks at Standard Doses Does Not Cause or Worsen Insulin Resistance or Endothelial Dysfunction in Lean or Obese Subjects Diabetes, November 1, 2006; 55(11): 3142 - 3150. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Qiu, R. K. Avramoglu, A. C. Rutledge, J. Tsai, and K. Adeli Mechanisms of glucosamine-induced suppression of the hepatic assembly and secretion of apolipoprotein B-100-containing lipoproteins J. Lipid Res., August 1, 2006; 47(8): 1749 - 1761. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Marshall Role of Insulin, Adipocyte Hormones, and Nutrient-Sensing Pathways in Regulating Fuel Metabolism and Energy Homeostasis: A Nutritional Perspective of Diabetes, Obesity, and Cancer Sci. Signal., August 1, 2006; 2006(346): re7 - re7. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |
